ZLAB on Nasdaq
Zai Lab Limited
Chinese pharmaceutical company based in Shanghai, listed on Nasdaq (ZLAB)1
In its 2026 annual report the company says: “We are a patient-focused, innovative, commercial-stage, global biopharmaceutical company with a substantial presence in both Greater China and the United States. We are focused on discovering, developing, and commercializing products that address medical conditions with significant unmet needs in the areas of oncology, immunology, neuroscience, and infectious disease.”7
Price unavailable
Last updated Oct 21, 2026.
Overview
Compare with Nature's Sunshine Products, Travere Therapeutics, Inc. or BridgeBio, or pick any stock.
- TickerZLAB on Nasdaq1
- Industrypharmaceutical industry1
- HeadquartersShanghai1
- Websitezailaboratory.com
- Incorporated inCayman Islands5
- Business address899 Halei Road, Building B, Pudong, Shanghai5
- Filer categoryLarge accelerated filer5
- Legal formcompany limited by shares3
- LEI549300P2UYQ9U5LY1T583
- StatusActive3
- LEI statusLapsed (not renewed)3
- Registered addressPO Box 311, KY1-1205 George Town, Cayman Islands3
See how the biggest companies compare on our leaderboards
We are a patient-focused, innovative, commercial-stage, global biopharmaceutical company with a substantial presence in both Greater China and the United States. We are focused on discovering, developing, and commercializing products that address medical conditions with significant unmet needs in the areas of oncology, immunology, neuroscience, and infectious disease. We intend to leverage our competencies and resources to positively impact human health. To that end, our experienced team has secured partnerships with leading global biopharmaceutical companies to generate a broad pipeline, including multiple commercial products and multiple programs in late-stage clinical development. We have also built an in-house R&D team with strong product discovery and translational research capabilities and are establishing a pipeline of proprietary product candidates with global rights.7 From its latest annual report
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Key numbers, fiscal 2025
-50.2%Operating margin4
-38.4%Net margin4
15.0%Revenue growth, 20254
-24.5%Return on equity4
-$158.9MFree cash flow4
What sells
Revenue by product, business segment and region, as the company reports it to the SEC.
Products and services
Zejula brought in 41% of the revenue Zai Lab Limited broke down this way in fiscal 2025.
Products and services by year
| Products and services | 2023 | 2024 | 2025 |
|---|---|---|---|
| Zejula | $168.8M | $187.1M | $189.0M |
| Vyvgart/Vyvgart Hytrulo | $10.0M | $93.6M | $94.2M |
| Nuzyra | $21.7M | $43.2M | $60.8M |
| Optune | $47.0M | $40.5M | $48.3M |
| Qinlock | $19.2M | $28.8M | $35.6M |
| Xacduro | $0 | $3.3M | $22.9M |
| Augtyro | $0 | $1.1M | $5.5M |
| Product and Service, Other | $0 | $0 | $717.0K |
Where the money goes
Where each dollar of revenue went, fiscal 2025
- Cost of revenue28¢$190.5M
- Research and development32¢$220.9M
- Selling, general and admin40¢$277.6M
- Income tax0¢$2.9M
Out of $457.2M in revenue.4 The company lost money this year.
Financial statements
Every line of the income statement as filed: the last 3 fiscal years, latest first.4
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Product revenue, net | $457.2M | $397.6M | $266.7M |
| Collaboration revenue | $3.0M | $1.4M | $0 |
| Total revenues | $460.2M | $399.0M | $266.7M |
| Cost of product revenue | -$190.5M | -$147.1M | -$95.8M |
| Cost of collaboration revenue | -$561.0K | -$742.0K | $0 |
| Research and development | -$220.9M | -$234.5M | -$265.9M |
| Selling, general, and administrative | -$277.6M | -$298.7M | -$281.6M |
| Gain on sale of intellectual property | $0 | $0 | $10.0M |
| Loss from operations | -$229.4M | -$282.1M | -$366.6M |
| Interest income | $33.0M | $37.1M | $39.8M |
| Interest expenses | -$5.2M | -$2.3M | $0 |
| Foreign currency gains (losses) | $19.6M | -$15.1M | -$14.8M |
| Other income, net | $3.5M | $5.3M | $7.0M |
| Loss before income tax | -$178.5M | -$257.1M | -$334.6M |
| Income tax benefit | $2.9M | $0 | $0 |
| Net loss | -$175.5M | -$257.1M | -$334.6M |
| Loss per share basic (in dollars per share) | -$0.16 | -$0.26 | -$0.35 |
| Loss per share diluted (in dollars per share) | -$0.16 | -$0.26 | -$0.35 |
| Weighted-average shares used in calculating net loss per ordinary share basic (in shares) | 1.1B shares | 989.5M shares | 966.4M shares |
| Weighted-average shares used in calculating net loss per ordinary share diluted (in shares) | 1.1B shares | 989.5M shares | 966.4M shares |
No quarter-by-quarter statement was filed.
Every line of the balance sheet as filed: the last 4 fiscal years (annual) or 4 quarters (quarterly), latest first.4
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Cash and cash equivalents | $679.6M | $449.7M | ||
| Restricted cash, current | $100.0M | $100.0M | ||
| Short-term investments | $10.0M | $330.0M | ||
| Accounts receivable (net of allowance for credit losses of $31 and $25 as of December 31, 2025 and 2024, respectively) | $106.1M | $85.2M | ||
| Notes receivable | $12.2M | $4.2M | ||
| Inventories, net | $74.7M | $39.9M | ||
| Prepayments and other current assets | $36.7M | $41.5M | ||
| Total current assets | $1.0B | $1.1B | ||
| Restricted cash, non-current | $1.1M | $1.1M | ||
| Property and equipment, net | $47.4M | $48.0M | ||
| Operating lease right-of-use assets | $19.2M | $21.5M | ||
| Land use rights, net | $2.9M | $2.9M | ||
| Intangible assets, net | $76.1M | $56.0M | ||
| Deferred tax assets | $3.4M | $0 | ||
| Other non-current assets | $3.1M | $5.8M | ||
| Total assets | $1.2B | $1.2B | ||
| Accounts payable | $141.6M | $100.9M | ||
| Current operating lease liabilities | $6.3M | $8.0M | ||
| Short-term debt | $204.5M | $131.7M | ||
| Other current liabilities | $63.7M | $58.7M | ||
| Total current liabilities | $416.2M | $299.4M | ||
| Deferred income | $27.3M | $31.4M | ||
| Non-current operating lease liabilities | $13.4M | $13.7M | ||
| Other non-current liabilities | $0 | $325.0K | ||
| Total liabilities | $456.9M | $344.9M | ||
| Ordinary shares (par value of $0.000006 per share; 5,000,000,000 shares authorized; 1,113,822,550 and 1,082,614,740 shares issued as of December 31, 2025 and 2024, respectively; 1,106,389,340 and 1,077,702,540 shares outstanding as of December 31, 2025 and 2024, respectively) | $7.0K | $7.0K | ||
| Additional paid-in capital | $3.3B | $3.3B | ||
| Accumulated deficit | -$2.6B | -$2.5B | ||
| Accumulated other comprehensive income | $29.7M | $50.5M | ||
| Treasury stock (at cost 7,433,210 and 4,912,200 shares as of December 31, 2025 and 2024, respectively) | -$29.1M | -$20.8M | ||
| Total shareholders equity | $715.5M | $840.9M | $796.1M | $1.0B |
| Total liabilities and shareholders equity | $1.2B | $1.2B | ||
| Accounts receivable, allowance for credit loss | $31.0K | $25.0K | ||
| Ordinary shares, par value (in dollars per share) | $0.00 | $0.00 | ||
| Ordinary shares, shares authorized (in shares) | 5.0B shares | 5.0B shares | ||
| Ordinary shares, shares issued (in shares) | 1.1B shares | 1.1B shares | ||
| Ordinary shares, shares outstanding (in shares) | 1.1B shares | 1.1B shares | ||
| Treasury stock (in shares) | 7.4M shares | 4.9M shares |
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Cash and cash equivalents | $679.6M | $449.7M | ||
| Restricted cash, current | $100.0M | $100.0M | ||
| Short-term investments | $10.0M | $330.0M | ||
| Accounts receivable (net of allowance for credit losses of $31 and $25 as of December 31, 2025 and 2024, respectively) | $106.1M | $85.2M | ||
| Notes receivable | $12.2M | $4.2M | ||
| Inventories, net | $74.7M | $39.9M | ||
| Prepayments and other current assets | $36.7M | $41.5M | ||
| Total current assets | $1.0B | $1.1B | ||
| Restricted cash, non-current | $1.1M | $1.1M | ||
| Property and equipment, net | $47.4M | $48.0M | ||
| Operating lease right-of-use assets | $19.2M | $21.5M | ||
| Land use rights, net | $2.9M | $2.9M | ||
| Intangible assets, net | $76.1M | $56.0M | ||
| Deferred tax assets | $3.4M | $0 | ||
| Other non-current assets | $3.1M | $5.8M | ||
| Total assets | $1.2B | $1.2B | ||
| Accounts payable | $141.6M | $100.9M | ||
| Current operating lease liabilities | $6.3M | $8.0M | ||
| Short-term debt | $204.5M | $131.7M | ||
| Other current liabilities | $63.7M | $58.7M | ||
| Total current liabilities | $416.2M | $299.4M | ||
| Deferred income | $27.3M | $31.4M | ||
| Non-current operating lease liabilities | $13.4M | $13.7M | ||
| Other non-current liabilities | $0 | $325.0K | ||
| Total liabilities | $456.9M | $344.9M | ||
| Ordinary shares (par value of $0.000006 per share; 5,000,000,000 shares authorized; 1,113,822,550 and 1,082,614,740 shares issued as of December 31, 2025 and 2024, respectively; 1,106,389,340 and 1,077,702,540 shares outstanding as of December 31, 2025 and 2024, respectively) | $7.0K | $7.0K | ||
| Additional paid-in capital | $3.3B | $3.3B | ||
| Accumulated deficit | -$2.6B | -$2.5B | ||
| Accumulated other comprehensive income | $29.7M | $50.5M | ||
| Treasury stock (at cost 7,433,210 and 4,912,200 shares as of December 31, 2025 and 2024, respectively) | -$29.1M | -$20.8M | ||
| Total shareholders equity | $715.5M | $840.9M | $796.1M | $1.0B |
| Total liabilities and shareholders equity | $1.2B | $1.2B | ||
| Accounts receivable, allowance for credit loss | $31.0K | $25.0K | ||
| Ordinary shares, par value (in dollars per share) | $0.00 | $0.00 | ||
| Ordinary shares, shares authorized (in shares) | 5.0B shares | 5.0B shares | ||
| Ordinary shares, shares issued (in shares) | 1.1B shares | 1.1B shares | ||
| Ordinary shares, shares outstanding (in shares) | 1.1B shares | 1.1B shares | ||
| Treasury stock (in shares) | 7.4M shares | 4.9M shares |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow as filed: the last 3 fiscal years, latest first.4
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Net loss | -$175.5M | -$257.1M | -$334.6M |
| Allowance for credit losses | $6.0K | $8.0K | $6.0K |
| Inventory write-down | $12.3M | $815.0K | $973.0K |
| Depreciation and amortization expenses | $15.0M | $11.9M | $9.0M |
| Impairment of property and equipment | $0 | $0 | $57.0K |
| Amortization of deferred income | -$5.3M | -$3.5M | -$3.4M |
| Share-based compensation | $65.6M | $70.7M | $79.6M |
| Loss (gain) from fair value changes of equity investment with readily determinable fair value | $1.9M | $6.1M | -$2.8M |
| Losses on disposal of property and equipment | $542.0K | $453.0K | $159.0K |
| Gain on disposal of land use right | $0 | $0 | -$408.0K |
| Noncash lease expenses | $8.8M | $8.4M | $8.7M |
| Gain from sale of intellectual property | $0 | $0 | -$10.0M |
| Foreign currency remeasurement impact | -$19.6M | $15.1M | $14.8M |
| Amortization of debt issuance cost | $194.0K | $700.0K | $0 |
| Accounts receivable | -$18.9M | -$27.0M | -$20.0M |
| Notes receivable | -$7.7M | $1.8M | $2.4M |
| Inventories | -$47.0M | $3.9M | -$14.9M |
| Prepayments and other current assets | $5.1M | -$18.7M | $12.2M |
| Deferred tax assets | -$3.3M | $0 | $0 |
| Other non-current assets | -$374.0K | -$1.4M | $187.0K |
| Accounts payable | $19.9M | -$2.2M | $36.8M |
| Other current liabilities | $4.8M | -$22.0M | $19.8M |
| Operating lease liabilities | -$7.5M | -$9.3M | -$8.4M |
| Deferred income | $745.0K | $6.6M | $11.2M |
| Other non-current liabilities | -$325.0K | $0 | $325.0K |
| Net cash used in operating activities | -$150.8M | -$214.9M | -$198.2M |
| Purchases of short-term investments | -$10.0M | -$330.0M | -$134.0M |
| Proceeds from maturity of short-term investment | $330.0M | $16.3M | $117.7M |
| Proceeds from the sale of equity investment | $1.2M | $0 | $0 |
| Purchases of property and equipment | -$8.1M | -$5.7M | -$7.2M |
| Proceeds from the sale of property and equipment | $87.0K | $29.0K | $122.0K |
| Acquisition of intangible assets | -$5.3M | -$55.9M | -$1.3M |
| Proceeds from sale of intellectual property | $0 | $0 | $10.0M |
| Proceeds from disposal of land use right | $0 | $0 | $3.9M |
| Net cash provided by (used in) investing activities | $307.9M | -$375.2M | -$10.8M |
| Proceeds from short-term debt | $206.8M | $131.6M | $0 |
| Repayment of short-term bank borrowings | -$138.9M | -$284.0K | $0 |
| Payments of debt issuance costs | -$194.0K | -$700.0K | $0 |
| Proceeds from exercises of stock options | $13.7M | $3.2M | $2.4M |
| Proceeds from issuance of ordinary shares upon public offerings | $0 | $217.3M | $0 |
| Payments of public offering costs | -$854.0K | -$1.3M | $0 |
| Taxes paid related to settlement of equity awards | -$8.2M | $0 | -$8.8M |
| Net cash provided by (used in) financing activities | $72.4M | $349.9M | -$6.4M |
| Effect of foreign exchange rate changes on cash, cash equivalents and restricted cash | $478.0K | -$310.0K | -$2.6M |
| Net increase (decrease) in cash, cash equivalents and restricted cash | $229.9M | -$240.5M | -$218.0M |
| Cash paid for interest | $4.9M | $2.0M | $0 |
| Payables for purchase of property and equipment | $486.0K | $449.0K | $2.5M |
| Payables for acquisition of intangible assets | $21.9M | $2.7M | $11.5M |
| Payables for public offering costs | $168.0K | $994.0K | $0 |
| Right-of-use asset acquired under operating leases | $6.0M | $15.2M | $3.7M |
| Receivables for stock option exercise under equity incentive plans | $0 | $70.0K | $0 |
No quarter-by-quarter statement was filed.
Corporate structure
Zai Lab Limited sits at the top of its group. 8 entities, 5 countries on record. Switch between the flow chart and the network, and select any entity to see its details.
Major holders of Zai Lab Limited
- TCG Crossover GP II, LLC Filed SCHEDULE 13G on Zai Lab Limited, latest Jun 11, 2026
- RA CAPITAL MANAGEMENT, L.P. Filed SCHEDULE 13G on Zai Lab Limited, latest Apr 6, 2026
- RTW INVESTMENTS, LP Filed SCHEDULE 13G on Zai Lab Limited, latest Feb 17, 2026 (3 filings since Aug 14, 2025)
- Capital World Investors Filed SCHEDULE 13G/A on Zai Lab Limited, latest Feb 13, 2026 (5 filings since Nov 10, 2021)
- Qiming Corporate GP IV, Ltd Filed SCHEDULE 13G/A on Zai Lab Limited, latest Feb 13, 2026
- Wellington Management Company Filed SCHEDULE 13G/A on Zai Lab Limited, latest Feb 10, 2026 (10 filings since Feb 4, 2022)
- FMR LLC Filed SCHEDULE 13G/A on Zai Lab Limited, latest Feb 5, 2026 (7 filings since Feb 9, 2022)
- Qiming Venture Partners IV, L.P. Filed SCHEDULE 13G/A on Zai Lab Limited, latest Aug 12, 2025 (3 filings since Feb 14, 2022)
- Janus Henderson Group Ltd. Filed SCHEDULE 13G/A on Zai Lab Limited, latest May 14, 2025 (3 filings since Nov 14, 2024)
- Invesco Filed SC 13G/A on Zai Lab Limited, latest Feb 1, 2024 (3 filings since Feb 14, 2022)
- BAILLIE GIFFORD & CO Filed SC 13G/A on Zai Lab Limited, latest Jul 5, 2022 (2 filings since Jan 27, 2022)
- Ying Du Filed SC 13G/A on Zai Lab Limited, latest Feb 14, 2022
- Zai Lab Limited Shanghai, China
- Zai Anti Infectives (Hong Kong) Limited Subsidiary · Hong Kong
- Zai Auto Immune (Hong Kong) Limited Subsidiary · Hong Kong
- Zai Lab (AUST) Pty. Ltd. Subsidiary · Australia
- Zai Lab (Hong Kong) Limited Subsidiary · Hong Kong
- Zai Lab (Taiwan) Limited Subsidiary · Taiwan
- Zai Lab (US) LLC Subsidiary · Delaware, United States
- ZL China Holding Two Limited Subsidiary · Hong Kong
Built from parent and subsidiary links from GLEIF, the Global Legal Entity Identifier Foundation (CC0); subsidiaries listed in Exhibit 21 of annual reports filed with the SEC; major holders from Schedules 13D and 13G. Each entity in the chart links to its source.
What it owns
What Zai Lab Limited reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.
Property and equipment
| Item | Latest | A year before | Change |
|---|---|---|---|
| Property and equipment, before depreciation | $89.6M4 Dec 31, 2025 | $85.1M4 Dec 31, 2024 | +5.3% |
| Accumulated depreciation | $42.2M4 Dec 31, 2025 | $37.1M4 Dec 31, 2024 | +13.6% |
| Property and equipment, net | $47.4M4 Dec 31, 2025 | $48.0M4 Dec 31, 2024 | −1.2% |
| Operating-lease assets (leased space) | $19.2M4 Dec 31, 2025 | $21.5M4 Dec 31, 2024 | −10.9% |
Investments
| Item | Latest | A year before | Change |
|---|---|---|---|
| Cash and cash equivalents | $679.6M4 Dec 31, 2025 | $449.7M4 Dec 31, 2024 | +51.1% |
| Marketable securities, current | $10.0M4 Dec 31, 2025 | $330.0M4 Dec 31, 2024 | −97.0% |
| Long-term investments | $3.1M12 Dec 31, 2024 | $9.2M12 Dec 31, 2023 | −66.2% |
Intangibles and goodwill
| Item | Latest | A year before | Change |
|---|---|---|---|
| Intangible assets, net (excluding goodwill) | $76.1M4 Dec 31, 2025 | $56.0M4 Dec 31, 2024 | +35.9% |
| Finite-lived intangibles, gross | $87.7M4 Dec 31, 2025 | $61.5M4 Dec 31, 2024 | +42.6% |
| Accumulated amortization | $11.5M4 Dec 31, 2025 | $5.4M4 Dec 31, 2024 | +111.9% |
| Finite-lived intangibles, net | $76.1M4 Dec 31, 2025 | $56.0M4 Dec 31, 2024 | +35.9% |
Inventory
| Item | Latest | A year before | Change |
|---|---|---|---|
| Inventory, total | $74.7M4 Dec 31, 2025 | $39.9M4 Dec 31, 2024 | +87.4% |
| Raw materials | $23.1M4 Dec 31, 2025 | $13.3M4 Dec 31, 2024 | +74.1% |
| Work in process | $5.8M4 Dec 31, 2025 | $2.5M4 Dec 31, 2024 | +127.6% |
| Finished goods | $45.8M4 Dec 31, 2025 | $24.1M4 Dec 31, 2024 | +90.5% |
Properties, in its own words
We lease our principal executive offices in Shanghai and Cambridge, Massachusetts as well as various administrative offices in Shanghai, Beijing, Guangzhou, Hong Kong, Taiwan, and South San Francisco, California and
research and development facilities in Shanghai and a small site in San Diego, California. We also lease two manufacturing facilities, including a small molecule and a large molecule facility, in Suzhou to support production of certain of our products and product candidates. In addition, we have completed the construction of a new office and research building in Suzhou. We believe these facilities are sufficient to meet our near-term needs.
Item 2 of the 10-K filed Feb 26, 2026.7
Leadership
Who has led Zai Lab Limited, and when. Pick a name to see everywhere that person has worked.
Chief executive
Chair
President
Chief financial officer
Chief operating officer
2025
- Chief executive officerYing Du Jan 4, 2021 to now19
- ChairYing Du Jan 4, 2021 to now19
- PresidentTao Fu Jan 4, 2021 to Oct 29, 202120
- PresidentYi Liang Jan 4, 2021 to Jun 27, 202221
- Chief financial officerYajing Chen Jul 17, 2023 to now22
- Chief financial officerWilliam Ki Chul Cho Jan 4, 2021 to Apr 5, 202323
- Chief operating officerJoshua L. Smiley Aug 3, 2022 to Aug 16, 202224
- Chief operating officerTao Fu Jan 4, 2021 to Oct 29, 202120
Board members and other officers (14)
- Operating PartnerYizhe Wang Jun 8, 2026 to now25
- OfficerRafael Amado Jan 3, 2023 to now26
- OfficerJoshua L. Smiley Apr 5, 2023 to now27
- Head of Global Dev., OncologyAlan B. Sandler Jan 4, 2021 to Jun 27, 202228
- Chief Medical OfficerHarald Reinhart Jan 4, 2021 to Jun 27, 202429
- Board memberMichel Vounatsos Jan 13, 2023 to now30
- Board memberJohn D. Diekman Jan 4, 2021 to now31
- Board memberLeon O. Moulder Jr. Jan 4, 2021 to now32
- Board memberNisa Leung Jan 4, 2021 to now33
- Board memberPeter Wirth Jan 4, 2021 to now34
- Board memberTao Fu Jan 4, 2021 to Oct 29, 202120
- Board memberWilliam Lis Jan 4, 2021 to now35
- Board memberScott W. Morrison Oct 18, 2021 to now36
- General counselFrazor Titus Edmondson Iii. Jan 4, 2021 to now37
Subsidiaries and ownership
Subsidiaries (Exhibit 21)
- ZL China Holding Two Limited Hong Kong6
- Zai Anti Infectives (Hong Kong) Limited Hong Kong6
- Zai Auto Immune (Hong Kong) Limited Hong Kong6
- Zai Lab (AUST) Pty. Ltd. Australia6
- Zai Lab (Hong Kong) Limited Hong Kong6
- Zai Lab (Taiwan) Limited Taiwan6
- Zai Lab (US) LLC Delaware6
The subsidiaries the company lists in Exhibit 21 of its annual report, as filed.
Former names
- Zai Lab LtdMay 30, 2017 to Oct 5, 20265
Timeline
- Aug 6, 20268-K Results of operations38
- Jun 17, 20268-K Shareholder vote39
- May 21, 20268-K Executive or director change40
- May 7, 20268-K Results of operations41
- Feb 26, 20268-K Results of operations42
- Nov 6, 20258-K Results of operations43
- Oct 16, 20258-K Entered a material agreement; New debt or obligation44
- Aug 7, 20258-K Results of operations45
- Jun 18, 20258-K Shareholder vote46
- May 8, 20258-K Results of operations47
- Feb 27, 20258-K Results of operations48
- Jan 3, 20258-K Entered a material agreement; New debt or obligation49
- Jan 4, 2021New chief executive Ying Du becomes CEO19
Calendar
Coming up
- Nov 5, 2026Reports results for the quarter ending Sep/2026 A year earlier it reported ($0.33) a share, on Nov 6, 2025.50
When it reported results
- Aug 6, 2026Reported quarterly or annual results38
- May 7, 2026Reported quarterly or annual results41
- Feb 26, 2026Reported quarterly or annual results42
- Nov 6, 2025Reported quarterly or annual results43
- Aug 7, 2025Reported quarterly or annual results45
- May 8, 2025Reported quarterly or annual results47
- Feb 27, 2025Reported quarterly or annual results48
- Nov 12, 2024Reported quarterly or annual results51
Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar
Filings
519 filings to the SEC since October 2021: 6 annual reports, 15 quarterly reports, 58 major events, 232 insider forms, 40 large holders, 168 other. The latest 20:
- Oct 5, 20264 EDGAR
- Aug 21, 20264 EDGAR
- Aug 20, 2026144 EDGAR
- Aug 19, 2026144 EDGAR
- Aug 18, 20264 EDGAR
- Aug 13, 20264 EDGAR
- Aug 13, 20264 EDGAR
- Aug 12, 2026144 EDGAR
- Aug 11, 2026144 EDGAR
- Aug 6, 202610-Q EDGAR
- Aug 6, 20268-K EDGAR
- Jul 6, 20264 EDGAR
- Jul 6, 20264 EDGAR
- Jul 1, 20264 EDGAR
- Jun 30, 2026144 EDGAR
- Jun 29, 20264 EDGAR
- Jun 29, 20264 EDGAR
- Jun 29, 20264 EDGAR
- Jun 26, 2026144 EDGAR
- Jun 26, 2026144 EDGAR
The 519 filings since October 2021 can be filtered by form type and year here when JavaScript is on.
Every filing from the last five years, summarized. The full record is on SEC EDGAR.
Insider trades
129 open-market trades by officers, directors and large owners since October 2021: 9 buys and 120 sales. Grants, option exercises and gifts are left out.
| Date | Who | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Aug 19, 2026 | Chen YajingChief Financial Officer | Sale | 260 | $27.00 | $7.0K | Form 4 |
| Aug 12, 2026 | Lis WilliamDirector | Sale | 8,506 | $25.00 | $212.7K | Form 4 |
| Aug 11, 2026 | Chen YajingChief Financial Officer | Sale | 619 | $25.00 | $15.5K | Form 4 |
| Jul 1, 2026 | GAYNOR RICHARDDirector | Buy | 1,736 | $19.05 | $33.1K | Form 4 |
| Jun 30, 2026 | Du YingChairperson & CEO | Sale | 7,026 | $18.53 | $130.2K | Form 4 |
| Jun 26, 2026 | Edmondson Frazor Titus IIIChief Legal Officer | Sale | 4,103 | $17.46 | $71.6K | Form 4 |
| Jun 26, 2026 | Du YingChairperson & CEO | Sale | 24,543 | $17.46 | $428.5K | Form 4 |
| Jun 26, 2026 | Chen YajingChief Financial Officer | Sale | 2,264 | $17.46 | $39.5K | Form 4 |
| Jun 22, 2026 | Lis WilliamDirector | Sale | 7,040 | $18.09 | $127.4K | Form 4 |
| May 18, 2026 | Du YingChairperson & CEO | Sale | 50,000 | $19.00 | $950.0K | Form 4 |
| May 15, 2026 | Du YingChairperson & CEO | Sale | 50,000 | $20.74 | $1.0M | Form 4 |
| May 14, 2026 | Edmondson Frazor Titus IIIChief Legal Officer | Sale | 3,517 | $20.19 | $71.0K | Form 4 |
| May 14, 2026 | Du YingChairperson & CEO | Sale | 50,000 | $20.09 | $1.0M | Form 4 |
| May 13, 2026 | Du YingChairperson & CEO | Sale | 50,000 | $19.97 | $998.3K | Form 4 |
| Apr 6, 2026 | Smiley Joshua LSee Remarks | Sale | 3,017 | $20.45 | $61.7K | Form 4 |
| Apr 6, 2026 | Edmondson Frazor Titus IIIChief Legal Officer | Sale | 1,224 | $20.45 | $25.0K | Form 4 |
| Apr 6, 2026 | Du YingChairperson & CEO | Sale | 2,653 | $20.45 | $54.3K | Form 4 |
| Apr 6, 2026 | Chen YajingChief Financial Officer | Sale | 853 | $20.45 | $17.4K | Form 4 |
| Apr 6, 2026 | Amado RafaelSee Remarks | Sale | 2,739 | $20.45 | $56.0K | Form 4 |
| Apr 2, 2026 | Smiley Joshua LSee Remarks | Sale | 9,614 | $20.39 | $196.0K | Form 4 |
All 129 trades can be filtered by person here when JavaScript is on.
From Forms 4 filed with the SEC.
Major holders
Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.
- TCG Crossover GP II, LLCSCHEDULE 13G, 1 filing Jun 11, 202652
- RA CAPITAL MANAGEMENT, L.P.SCHEDULE 13G, 1 filing Apr 6, 202653
- RTW INVESTMENTS, LPSCHEDULE 13G, 3 filings Aug 14, 2025 to Feb 17, 202654
- Capital World InvestorsSCHEDULE 13G/A, 5 filings Nov 10, 2021 to Feb 13, 202655
- Qiming Corporate GP IV, LtdSCHEDULE 13G/A, 1 filing Feb 13, 202656
- Wellington Management CompanySCHEDULE 13G/A, 10 filings Feb 4, 2022 to Feb 10, 202657
- FMR LLCSCHEDULE 13G/A, 7 filings Feb 9, 2022 to Feb 5, 202658
- Qiming Venture Partners IV, L.P.SCHEDULE 13G/A, 3 filings Feb 14, 2022 to Aug 12, 202559
- Janus Henderson Group Ltd.SCHEDULE 13G/A, 3 filings Nov 14, 2024 to May 14, 202560
- InvescoSC 13G/A, 3 filings Feb 14, 2022 to Feb 1, 202461
- BAILLIE GIFFORD & COSC 13G/A, 2 filings Jan 27, 2022 to Jul 5, 202262
- Ying DuSC 13G/A, 1 filing Feb 14, 202263
Executive pay
What the company paid its top executives, from the summary compensation table in its proxy statement. Total pay includes salary, bonus, stock and option awards and other pay, as the company valued them.
| Year | Executive | Age | Salary | Total pay |
|---|---|---|---|---|
| 2025 | Samantha (Ying) Du, | 61 | $908.7K | $10.7M64 |
| 2025 | Josh Smiley | 56 | $672.8K | $4.7M64 |
| 2025 | Rafael Amado | 62 | $641.7K | $4.0M64 |
| 2025 | F. Ty Edmondson | 60 | $590.9K | $3.3M64 |
| 2025 | Yajing Chen | 58 | $520.0K | $3.2M64 |
| 2024 | Chief Executive Officer and Chairperson of the Board of Directors | $901.0K | $9.1M64 | |
| 2024 | President and Chief Operating Officer | $667.1K | $5.5M64 | |
| 2024 | PresidentHead of Global Research and Development | $636.3K | $3.6M64 | |
| 2024 | Chief Legal Officer and Corporate Secretary | $585.9K | $2.8M64 | |
| 2024 | Chief Financial Officer | $502.5K | $2.6M64 | |
| 2023 | Chief Executive Officer and Chairperson of the Board of Directors | $868.5K | $12.0M64 | |
| 2023 | President and Chief Operating Officer | $637.5K | $5.6M64 | |
| 2023 | PresidentHead of Global Research and Development | $620.0K | $4.9M64 | |
| 2023 | Chief Financial Officer | $424.4K | $2.0M64 |
Held by these funds
The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 93. Change is in shares since the quarter before.
| Fund | Shares | Value | Share of the fund | Change |
|---|---|---|---|---|
| Rtw Investments, LP | 6,574,032 | $124.9M | 1.1% | No change |
| TCG Crossover Management, LLC | 6,137,627 | $116.6M | 2.8% | New |
| Ra Capital Management, L.P. | 5,743,533 | $109.1M | 0.9% | +36,271 |
| ADAR1 Capital Management, LLC | 3,369,034 | $64.0M | 3.0% | +1,943,667 |
| Fmr LLC | 2,815,214 | $53.5M | 0.0% | +1,552,823 |
| Goldman Sachs Group Inc | 2,315,480 | $44.0M | 0.0% | +2,204,893 |
| Woodline Partners LP | 2,207,293 | $41.9M | 0.1% | New |
| Frazier Life Sciences Management, L.P. | 1,902,320 | $36.1M | 0.8% | No change |
| Bamco Inc /ny/ | 1,623,694 | $30.9M | 0.0% | −34,624 |
| Two Sigma Investments, LP | 1,299,394 | $24.7M | 0.0% | +989,671 |
| Citadel Advisors LLC | 1,284,706 | $24.4M | 0.0% | −403,926 |
| Rock Springs Capital Management LP | 814,707 | $15.5M | 0.8% | No change |
| BlackRock, Inc. | 664,462 | $12.6M | 0.0% | −200,684 |
| Jane Street Group, LLC | 476,541 | $9.1M | 0.0% | +208,615 |
| B Group, Inc. | 450,646 | $8.6M | 4.9% | No change |
| Nantahala Capital Management, LLC | 400,000 | $7.6M | 0.2% | New |
| Schroder Investment Management Group | 393,167 | $7.2M | 0.0% | No change |
| Nan Fung Trinity (hk) Ltd | 346,466 | $6.6M | 0.6% | No change |
| Aberdeen Group plc | 311,294 | $5.9M | 0.0% | +73,555 |
| Citigroup Inc | 300,775 | $5.7M | 0.0% | +299,816 |
| Spruce Street Capital LP | 279,110 | $5.3M | 1.0% | New |
| Ameriprise Financial Inc | 253,171 | $4.8M | 0.0% | +9,614 |
| BNP PARIBAS ASSET MANAGEMENT Holding S.A. | 246,982 | $4.7M | 0.0% | +130,422 |
| Hennion & Walsh Asset Management, Inc. | 230,418 | $4.4M | 0.1% | +16,095 |
| Hudson Bay Capital Management LP | 215,000 | $4.1M | 0.0% | +185,000 |
13F reports cover disclosed long positions in U.S. stocks only.
SEC filer profile
How Zai Lab Limited is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.
- Name on EDGARZai Lab Ltd2
- CIK0001704292
- Employer ID (EIN)98-11445957
- Filer statusLarge accelerated filer not an emerging growth company; not a smaller reporting company; not a shell company7
- Incorporated inCayman Islands7
- Fiscal year endsDecember 312
- Industry code (SIC)2834 Pharmaceutical Preparations2
- SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance2
- Business address899 Halei Road, Building B, Pudong, Shanghai, China2
- Phone8621616325882
- Shares outstanding1,106,407,390 Common Stock shares; 307,140,690 Adr shares as of Feb 20, 20267
- Public float$3.8B as of Jun 30, 20257
- AuditorKPMG LLP, Short Hills, New Jersey PCAOB ID 185; it also attests to the company’s internal control over financial reporting7
- On EDGAR sinceMay 30, 20172
- Filings736 in all: 4 (256), 144 (116), 8-K (71), 6-K (55), SC 13G/A (31), 3 (21), 10-Q (17), CORRESP (16)2
All 45 form types
UPLOAD (16), SC 13G (14), SCHEDULE 13G/A (13), 424B5 (8), DEF 14A (7), DEFA14A (7), PRE 14A (7), 10-K (6), 4/A (6), S-8 (6), SCHEDULE 13G (6), F-1/A (5), ARS (4), CT ORDER (4), DRSLTR (4), 20-F (3), 20-F/A (3), 5 (3), DRS/A (3), EFFECT (3), 3/A (2), 424B2 (2), 424B4 (2), 8-K/A (2), DRS (2), F-1 (2), S-3ASR (2), SEC STAFF LETTER (2), 10-K/A (1), 144/A (1), 424B3 (1), 8-A12B (1), F-1MEF (1), F-3ASR (1), F-6 (1), F-6EF (1), POSASR (1)
- Latest filingsAnnual report (10-K) Feb 26, 2026
Quarterly report (10-Q) Aug 6, 2026
Proxy statement (DEF 14A) Apr 28, 2026
Latest 8-K (8-K) Aug 6, 2026
Securities registered for trading
| Class | Symbol | Exchange |
|---|---|---|
| American Depositary Shares, each representing 10 Ordinary Shares, par value $0.000006 per share | ZLAB | The Nasdaq Global Market |
| Ordinary Shares, par value $0.000006 per share | 9688 |
From the cover page of the 10-K filed Feb 26, 2026 (Section 12(b) of the Exchange Act).7
Risk factors and legal proceedings
The risks Zai Lab Limited names in Item 1A of its 10-K filed Feb 26, 2026: 75 risks under these headings, as written.7
- Risks Related to Doing Business in China
- Uncertainties in the Chinese legal system could materially and adversely affect us.
- Changes in relations between the United States and China, as well as relations between China and other countries, may adversely impact our business, financial condition, and results of operations.
- The Chinese government may intervene in or influence our business, which could result in a material change in our operations, strategy, research and development activities, commercial activities, business, financial condition, results of operations, prospects, and the value of our securities.
- Because the majority of our operations are in mainland China, there have been concerns regarding oversight of audits of our financial statements filed with the SEC.
- We may be subject to additional approval, filing, and compliance obligations with Chinese authorities in connection with our engagement of KPMG LLP, a U.S. auditor that is subject to PCAOB inspection.
- We are subject to extensive data protection, privacy, and information security laws, regulations, and policies in China. Compliance with such laws, rules, and regulations, and any other future laws and regulations in these areas, may entail significant expenses and could materially affect our business and results of operations, including as a result of government enforcement actions and significant penalties.
- The economic, political, and social conditions in mainland China, as well as governmental policies, could affect the business environment and financial markets in mainland China and our ability to operate our business, financial condition, results of operations, and prospects.
- We are required to obtain certain approvals and licenses from Chinese authorities to operate our Chinese subsidiaries.
- Under Chinese laws and regulations, we may be required by the CSRC or other Chinese regulatory authorities to obtain approval or follow certain procedures to issue our securities to foreign investors, and we cannot predict whether or when we will be able to obtain such approval or complete such procedures.
- We may be exposed to liabilities under anti-corruption, anti-bribery, and anti-fraud laws in China and the United States, including the FCPA, and any allegation, investigation, or determination that we, or our employees or contracted third parties, have violated such laws could have a material adverse effect on our business or reputation.
- Restrictions on currency exchange may limit our ability to receive and use financing in foreign currencies effectively.
The other 64 risks
- We may rely on dividends and other distributions on equity paid by our Chinese subsidiaries to fund any cash and financing requirements we may have, and any limitation on the ability of our Chinese subsidiaries to make payments to us could have a material adverse effect on our business operations.
- Chinese regulations relating to the establishment of offshore special purpose companies by residents in mainland China may subject our China resident beneficial owners or our wholly foreign-owned subsidiaries in mainland China to liability or penalties, limit our ability to inject capital into these subsidiaries, limit the ability of these subsidiaries to increase their registered capital or distribute profits to us, or otherwise adversely affect us.
- Chinese regulations establish complex procedures for certain acquisitions of mainland China based companies by foreign investors, which could make it more difficult for us to pursue growth through acquisitions in mainland China.
- Completing the necessary inspection and approval processes for our Chinese manufacturing facilities, such as by the FDA, NMPA, and EMA, may be time consuming and costly.
- Our business benefits from certain financial incentives and discretionary policies granted by local governments. Expiration of, or changes to, these incentives or policies would have an adverse effect on our business, financial condition, and results of operations.
- It may be difficult for shareholders and regulators outside of mainland China to conduct investigations or collect evidence in mainland China.
- If we are classified as a Chinese resident enterprise for Chinese income tax purposes, such classification could result in unfavorable tax consequences to us and our non-Chinese shareholders or ADS holders.
- We and our shareholders may face tax consequences and other requirements in mainland China with respect to indirect transfers of equity interests in Chinese resident enterprises.
- Certain of our investments may be subject to review from the Committee on Foreign Investment in the United States, which may delay or block a transaction from closing.
- Changes in United States and international trade policies and relations, particularly with regard to China, may adversely impact our business, financial condition, and results of operations.
- It may be difficult to enforce against us or our management in mainland China any judgments obtained from foreign courts.
- Failure to renew our current leases or locate desirable alternatives for our leased properties could materially and adversely affect our business.
- Risks Related to Our Financial Position
- We have incurred significant losses since our inception and anticipate that we will continue to incur losses for at least the next few quarters. If we are unable to generate sufficient revenue from our commercial products, on the anticipated timeline or at all, at a level that more than offsets our expenses, we will be unable to achieve or maintain profitability.
- We may seek additional funding, such as for our product development programs and commercialization efforts, which may not be available on acceptable terms or at all. If we are unable to raise capital on acceptable terms when needed, we could be forced to delay, reduce, or terminate certain programs or activities.
- We and our subsidiaries have entered into debt arrangements with certain financial institutions in China, and we may in the future consider additional debt arrangements, to fund our business or working capital needs. Such debt arrangements may restrict our future operations.
- We may enter into certain capital raising, business collaboration, or other arrangements that may cause dilution to our shareholders, restrict our operations, or require us to relinquish rights to our technologies or product candidates.
- We may not be able to access the capital and credit markets on terms that are favorable to us.
- Our results of operations may be adversely affected by sustained periods of increased inflation.
- Risks Related to Our Business and Industry
- Our ability to generate revenues is highly dependent on the success of our commercial products and our ability to obtain regulatory approvals for our product candidates.
- If we are not successful in gaining broad acceptance of our commercial products, our business would be harmed.
- We may not obtain regulatory approval of our product candidates, on the anticipated timeline or at all, which could delay or limit our ability to realize the full potential of our product pipeline.
- We have limited experience manufacturing our products and product candidates on a large clinical or commercial scale. We rely on third parties for our supply chain, and if we experience problems with any of these third parties, the manufacture of our products or product candidates could be delayed, which could harm our business and results of operations.
- If our manufacturing facilities are damaged or destroyed, or production at such facilities is otherwise interrupted, or if any new manufacturing facilities are not approved by regulators, our business and prospects would be negatively affected.
- We have a limited operating history, which may make it difficult for you to evaluate the success of our business and to assess our future prospects.
- We may decide to pursue a particular product, product candidate, or indication and fail to pursue other products, product candidates, or indications that may later prove to be more profitable or for which there is a greater likelihood of success.
- The market opportunities for certain of our products and product candidates may be small, such as when those opportunities are limited to patients who are ineligible for other treatment options or who have not responded to prior treatments, and our estimations with respect to these populations may be inaccurate.
- The pharmaceutical industry is highly regulated, and such regulations are subject to change, which may affect the approval and commercialization of our products and product candidates, and any failure to comply with such regulations could have adverse legal and financial impact.
- If safety, efficacy, manufacturing, or supply issues arise with any therapy or treatment that we use in combination with our products and product candidates, such as chemotherapy drugs, we may be unable to market such products or product candidate or may experience significant regulatory delays or supply shortages, and our business could be materially harmed.
- We face substantial competition, which may result in our competitors discovering, developing, or commercializing drugs before or more successfully than we do, or developing products or therapies that are more advanced or effective than ours, which may adversely affect our financial condition and our ability to successfully market or commercialize our products and product candidates.
- Clinical development involves a lengthy and expensive process with an uncertain outcome.
- We may incur additional costs or experience delays in completing pre-clinical or clinical trials or ultimately be unable to complete the development and commercialization of our product candidates.
- If we experience delays or difficulties in the enrollment of patients in clinical trials, the progress of such clinical trials and our receipt of necessary regulatory approvals could be delayed or prevented.
- Our products and product candidates may cause undesirable side effects that could delay or prevent their regulatory approval, limit the commercial profile of an approved label, or result in significant negative consequences following any regulatory approval.
- If we are unable to obtain NMPA approval for our products and product candidates to be eligible for an expedited registration pathway, the time and cost we incur to obtain regulatory approvals may increase. Even if we receive a Category 1 drug designation, it may not lead to a faster development, review, or approval process.
- We continue to be subject to ongoing obligations and continued regulatory review with respect to our commercial products, which may result in significant additional expense, and if we fail to comply with ongoing regulatory requirements or experience any unanticipated problems with any of our commercial products, we may be subject to penalties.
- Our future success depends on our ability to retain key executives and to attract, retain, and motivate qualified personnel.
- As the Company develops globally, we may increase the size and capabilities of our organization, and we may experience difficulties in managing such growth.
- We may explore additional regional or global licensing or collaboration arrangements for the development and/or commercialization of product candidates, which may expose us to significant additional costs, such as upfront fees, milestone payments, royalty payments, and the costs of related clinical or pre-clinical trials, may divert management attention or resources away from our other products and product candidates, and may expose us to additional risks of conducting business in additional international markets.
- We may engage in future partnerships, in-licensing arrangements, joint ventures, or other types of business acquisitions that could disrupt our business, cause dilution to holders of our securities, and harm our financial condition and operating results.
- We may need to significantly reduce our prices for our approved products in mainland China to be included in the NRDL for reimbursement, which could diminish our sales or adversely affect our profitability.
- Companies in mainland China that manufacture or sell drugs and medical devices are required to comply with extensive regulations and hold a number of permits and licenses to carry on their business. Our ability to obtain and maintain these regulatory approvals is uncertain, and future government regulation may place additional burdens on our efforts to commercialize our products and product candidates.
- If we fail to maintain our licenses or other intellectual property-related agreements for our products or product candidates or if we otherwise experience disruptions or disputes relating to our business relationships, we could lose the ability to continue the development and commercialization of our products and product candidates, and such disputes could cause us to use substantial resources.
- Reputational harm to our products, including product liability claims or lawsuits against us or any of our licensors, could cause us to incur substantial liabilities or loss of revenue or harm our reputation.
- Potential cybersecurity threats are changing rapidly and advancing in sophistication. We may not be able to protect our systems and networks, or the confidentiality of our confidential or other information (including personal information), from cyberattacks and other unauthorized access, disclosure, and disruption.
- We may experience operational, regulatory, and competitive risks due to our use of artificial intelligence.
- We, our employees, and our contracted third parties are subject to laws and government regulations relating to privacy and data protection that have required us to modify certain of our policies and procedures with respect to the collection and processing of personal data, and future laws and regulations may cause us to incur additional expenses or otherwise limit our ability to collect and process personal data.
- We may face further restrictions (or even prohibitions) on our ability to transfer our scientific data abroad if Chinese regulators impose new restrictions (or change their interpretation of existing restrictions) on life sciences companies like us and the scientific data we obtain, generate, and maintain.
- Risks Related to Our Dependence on Third Parties
- We rely on third parties, including our licensors, CMOs, and other suppliers, to support the commercial and clinical supply of our products and product candidates. Failure of such third parties to supply us with a sufficient quantity of products, in a timely matter or at all, may adversely affect our business.
- We rely on third parties to conduct our pre-clinical and clinical trials. If these third parties do not successfully carry out their contractual duties or meet expected deadlines, we may not be able to obtain regulatory approval for or commercialize our products or product candidates and our business could be substantially harmed.
- If we lose our relationships with CROs, our product development efforts could be delayed.
- We depend on other parties to manage certain intellectual property rights that are material to our business. Any failure to effectively protect these rights could adversely affect our business and operations.
- We rely on third-party distributors to sell our commercial products, and a limited number of customers have generated a substantial portion of our revenue. If we fail to maintain an effective distribution channel for our products, our business and sales of the relevant products could be adversely affected.
- The illegal distribution and sale by third parties of counterfeit versions of our products or stolen products could have a negative impact on our reputation and business.
- Our business, results of operations, and financial condition may be adversely affected by deterioration in the credit quality of, or defaults by, our customers, and our deposits and investments may be negatively affected by fluctuations in interest rates.
- Risks Related to Intellectual Property
- If we are unable to obtain and maintain protection for our products and product candidates through intellectual property rights, or if the scope of such intellectual property rights obtained is not sufficiently broad, third parties may compete directly against us.
- Our owned or in-licensed patents could be found invalid or unenforceable if challenged in court or before the U.S. Patent and Trademark Office or other foreign authority.
- We may not be able to protect our intellectual property.
- Developments or uncertainties in patent law could have a negative impact on our business.
- If we are unable to maintain the confidentiality of our trade secrets, our business and competitive position may be harmed.
- If our products or product candidates infringe, misappropriate, or otherwise violate the intellectual property rights of third parties, we may incur substantial liabilities, and we may be unable to sell or commercialize these products and product candidates.
- Intellectual property litigation and proceedings could cause us to spend substantial resources and distract our personnel from their normal responsibilities.
- We may be subject to claims that we or our employees, consultants, or advisors have wrongfully used or disclosed alleged trade secrets of their current or former employers or are in breach of confidentiality, non-disclosure, non-use, non-competition, or non-solicitation agreements with such current or former employers, some of whom may be our competitors or potential competitors.
- We may not be successful in obtaining intellectual property rights for acquired or in-licensed product candidates.
- If we or our licensors or collaboration partners do not obtain patent term extension and data exclusivity for our products or their products or any product candidates we may develop, our business may be materially harmed.
Legal proceedings
We are, from time to time, subject to various claims, lawsuits, and other legal and administrative proceedings arising in the ordinary course of business. Some of these claims, lawsuits, and other proceedings may involve highly complex issues that are subject to substantial uncertainties and could result in damages, fines, penalties, non-monetary sanctions, or relief. However, we do not consider any such claims, lawsuits, or proceedings that are currently pending, individually or in the aggregate, to be material to our business or likely to result in a material adverse effect on our future operating results, financial condition, or cash flows.
The opening of Item 3, Legal Proceedings.7
Links
- Websitezailaboratory.com1
- X (Twitter)x.com/ZaiLab_Global1
- LinkedInwww.linkedin.com/company/zai-lab1
- WikidataQ106221884
- SEC EDGARCIK 1704292
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1WikidataZai Lab Limited on Wikidata
- 2SEC EDGARZai Lab Limited filings on SEC EDGAR
- 3
- 4SEC EDGARZai Lab Limited 10-K for fiscal 2025
- 5SEC EDGARZai Lab Limited filings on SEC EDGAR
- 6
- 7
- 8SEC EDGARZai Lab Limited 10-K for fiscal 2018
- 9SEC EDGARZai Lab Limited 10-K for fiscal 2019
- 10SEC EDGARZai Lab Limited 10-K for fiscal 2020
- 11SEC EDGARZai Lab Limited 10-K for fiscal 2021
- 12SEC EDGARZai Lab Limited 10-K for fiscal 2022
- 13SEC EDGARZai Lab Limited 10-K for fiscal 2018
- 14SEC EDGARZai Lab Limited 10-Q for fiscal 2025
- 15SEC EDGARZai Lab Limited 10-Q for fiscal 2025
- 16SEC EDGARZai Lab Limited 10-Q for fiscal 2026
- 17SEC EDGARZai Lab Limited 10-K for fiscal 2018
- 18SEC EDGARZai Lab Limited 10-Q for fiscal 2025
- 19SEC EDGARYing Du, Chief executive officer
- 20SEC EDGARTao Fu, President
- 21SEC EDGARYi Liang, President
- 22SEC EDGARYajing Chen, Chief financial officer
- 23
- 24
- 25SEC EDGARYizhe Wang, Operating Partner
- 26SEC EDGARRafael Amado, Officer
- 27SEC EDGARJoshua L. Smiley, Officer
- 28
- 29
- 30SEC EDGARMichel Vounatsos, Board member
- 31SEC EDGARJohn D. Diekman, Board member
- 32SEC EDGARLeon O. Moulder Jr., Board member
- 33SEC EDGARNisa Leung, Board member
- 34SEC EDGARPeter Wirth, Board member
- 35SEC EDGARWilliam Lis, Board member
- 36SEC EDGARScott W. Morrison, Board member
- 37
- 38SEC EDGARResults of operations
- 39SEC EDGARShareholder vote
- 40SEC EDGARExecutive or director change
- 41SEC EDGARResults of operations
- 42SEC EDGARResults of operations
- 43SEC EDGARResults of operations
- 44
- 45SEC EDGARResults of operations
- 46SEC EDGARShareholder vote
- 47SEC EDGARResults of operations
- 48SEC EDGARResults of operations
- 49
- 50NasdaqNasdaq calendar
- 51
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60
- 61SEC EDGARInvesco SC 13G/A on Zai Lab Limited
- 62
- 63SEC EDGARYing Du SC 13G/A on Zai Lab Limited
- 64